Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (3135)	2/3/2011 10:13:01 AM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

MRNA was up 27.71% at the opening, after some news.<g> finance.yahoo.com But now is up only 10.58%.<g> bigcharts.marketwatch.com Volume is already getting close to 1.5M, about 5.5x its ADV. The ACTAY is $3.88, which would be a good % gain from present levels. But with some good news the stock still has room to run and could get to the $8 level.<g> bigcharts.marketwatch.com Disclosure: I am still long MRNA, but took some profits on today's spike.<g> Bernard

To: Jibacoa who wrote (3135)	9/8/2011 3:58:27 PM
From: Jibacoa	Respond to of 3722

RE: OPK's recent news.<g> The news on Tuesday that OPK had been awarded a $200,000 research grant from the University of Pennsylvania Center for Orphan Disease Research and Therapy to develop a therapeutic agent to treat Mucopolysaccharidoses Type I (MPS I) has to do with the technology that OPK acquired when it bought CURNA in February. http://finance.yahoo.com/news/OPKO-Health-Announces-Grant-bw-1126788992.html?x=0&.v=1 "CURNA's broad platform technology is based on the up-regulation of protein production through interference with non-coding RNA's (natural antisense). This strategy is unique and contrasts with established approaches whichdown-regulate protein production. CURNA has designed a novel type of therapeutic modality, termed AntagoNAT, and has validated this approach forup-regulation of several therapeutically relevant proteins. CURNA's technology, exclusively licensed from The Scripps Research Institute, was developed by Dr. Claes Wahlestedt, a founder of CURNA. CURNA has developed and patented molecules which increase the production of over 90 key proteins involved in a large number of individual diseases." http://investor.opko.com/releasedetail.cfm?ReleaseID=546733 The stock needs to deal with the resistance at the $4.25 and $4.50 levels. bigcharts.marketwatch.com Before it can think of re-testing its February Hs around $5.05 <g> bigcharts.marketwatch.com The ACTAY is 6 Today's volume of > 1.7mm is already ahead of its ADV as the stock has had some good volume upticks in the last hour although it has been having some downticks while I am witting and is still questionable if it will be able to close on the black today. <g> It seems that with some good news, the stock could get to re-test the Feb's Hs, or even reach the ACTAY level. <g> Of course, if we get a better market environment and or some of the expected news on Rolapitant, the drug it bought from Shering, which has good potential for approval for post-operative nausea, or for the nausea associated whith chemotherapy, the stock could have some better moves.<g> It seems OPK bought Rolapitant at a god price, <g> shearlingsplowed.blogspot.com Another item that also could make the stock go higher is some news on its test for AD. On the slides from OPKO's presentation in June at Jefferies, which were the same it presented at its annual meeting that same week, they said that R&D was expected to be completed by "late Summer"" and were "planning for product launch". <g> See Slide No. 15 sec.gov At any rate, wll see how it closes. Disclosure: I am long OPK Bernard